Floatz logo

ELGEMTUMAB

Squamous Cell Carcinoma of Head and Neck

Novartis Pharmaceuticalsmonoclonal_antibodyPhase 1Dormant
CC
44/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
81/ 100

Competitive context

250 Active assets in the Squamous Cell Carcinoma of Head and Neck cohort.

Asset / SponsorPhaseRating
Carboplatin
Akeso
Phase 4BB
CIS-DIAMMINEDICHLOROPLATINUM II
Akeso
Phase 3BB
Irinotecan
Neonc Technologies, Inc.
Phase 2BB
Tisotumab Vedotin
Seagen, a wholly owned subsidiary of Pfizer
Phase 2BB
Capecitabine
Merck Sharp & Dohme LLC
Phase 2BB

View all 50 →

Same molecule, other indications

ELGEMTUMAB is also rated in:

Advanced HER2-positive Breast Cancer or Gastric CancerDormant
CC
Indicative ·
47 / 100
View asset →
HER2 + Breast Cancer, HER2 + Gastric Cancer, Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell CarcinomaDormant
CC
Indicative ·
47 / 100
View asset →
gastric cancerDormant
CC
Indicative ·
47 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →